Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study
Open Access
- 1 November 2017
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 45 (1) , 32-39
Abstract
Objective.: Assess whether baseline anticyclic citrullinated peptide antibodies (anti-CCP) status is associated with treatment response in patients with rheumatoid arthritis (RA) initiating abatacept (ABA) or a tumor necrosis factor-α inhibitor (TNFi).Methods.: Using the Corrona RA registry, patients were identified who initiated ABA or a TNFi (June 2004–January 2015), had a followup visit 6 months (± 3 mos) after initiation, and anti-CCP measured at or prior to initiation. Primary outcome was mean change in Clinical Disease Activity Index (CDAI) from initiation to 6 months. Treatment response was evaluated based on a typical patient profile (female, aged 57 yrs, body mass index of 30 kg/m2, baseline CDAI of 20, 1 prior biologic, and no comorbidities other than RA). Secondary outcomes included remission and low disease activity.Results.: There were 566 ABA initiators [anti-CCP+ (≥ 20 units/ml): n = 362; anti-CCP− (< 20 units/ml): n = 204] and 1715 TNFi initiators (anti-CCP+: n = 1113; anti-CCP−: n = 602). Differences between treatment groups included baseline disease duration, CDAI, and prior biologic use. At 6 months, anti-CCP+ ABA initiators were associated with significantly greater CDAI response versus anti-CCP− ABA initiators; no significant difference was observed for TNFi initiators. When considering a typical RA patient profile, CDAI response was greater in anti-CCP+ versus anti-CCP− ABA initiators; anti-CCP+ versus anti-CCP− TNFi initiators were similar. Secondary outcome responses were also greater in anti-CCP+ versus anti-CCP− ABA initiators; TNFi initiators did not differ by anti-CCP status.Conclusion.: In a US-based clinical practice setting, anti-CCP status was associated with a differential treatment response to ABA, but not TNFi.Keywords
This publication has 15 references indexed in Scilit:
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2015
- Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritisAnnals of the Rheumatic Diseases, 2015
- Abatacept Reduces Levels of Switched Memory B Cells, Autoantibodies, and Immunoglobulins in Patients with Rheumatoid ArthritisThe Journal of Rheumatology, 2014
- The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-AnalysisPLOS ONE, 2014
- CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patientsBMC Immunology, 2013
- Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practiceArthritis Care & Research, 2012
- Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid ArthritisThe Journal of Rheumatology, 2012
- A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis RegistriesSeminars in Arthritis and Rheumatism, 2010
- Use and significance of anti-CCP autoantibodies in rheumatoid arthritisRheumatology, 2005
- Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritisArthritis Research & Therapy, 2005